Drugs / QRH-882260
QRH-882260
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02574858 | Nov 2015 → Aug 2016 | — | University of Michigan | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QRH-882260 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02574858 ↗ |
| Known as | Fluorescence peptide qrh-882260 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594489 ↗ |
| Known as | Qrhkpre-gggsk-(cy5)-nh2 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594489 ↗ |
| Modality | Peptide | “The investigational agent to be used in this study is a fluorescently-labeled peptide composed of a 7-amino acid sequence attached to Cy5.” NCT02574858 ↗ |
| Route | Oral | “orally administered QRH-882260” NCT02574858 ↗ |
| Target | EGFR | “a topically administered Cy5-labeled heptapeptide specific for epithelial growth factor receptor (EGFR)” NCT02574858 ↗ |